RecruitingPhase 2NCT07224672

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis

A Phase 2, Open-label, Randomized, Dose Optimization Study Evaluating the Efficacy and Safety of Belantamab Mafodotin Administered in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain Amyloidosis (ALANIS)

Sponsor

GlaxoSmithKline

Enrollment

60 participants

Start Date

Jun 24, 2026

Study Type

INTERVENTIONAL

Conditions

Amyloidosis

Summary

The study aims to evaluate the efficacy and safety of belantamab mafodotin in combination with cyclophosphamide, bortezomib, and dexamethasone in adult participants with newly diagnosed (ND) AL amyloidosis .

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Belantamab mafodotin, a drug called Bortezomib, and others for people with amyloidosis. The study is currently recruiting participants at 5 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGBelantamab mafodotin

Belantamab mafodotin will be administered

DRUGCyclophosphamide

Cyclophosphamide will be administered

DRUGBortezomib

Bortezomib will be administered

DRUGDexamethasone

Dexamethasone will be administered

Locations(5)

GSK Investigational Site

Rochester, Minnesota, United States

GSK Investigational Site

Westmead, New South Wales, Australia

GSK Investigational Site

Woolloongabba, Queensland, Australia

GSK Investigational Site

Box Hill, Victoria, Australia

GSK Investigational Site

Frankston, Victoria, Australia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07224672

Related Trials

A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.

NCT0708164618 locations

Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

NCT06563895103 locations

Dietary Reporting In The Amyloidoses

NCT057380051 location

Prevalence and Significance of ATTR Aortic Valve Amyloidosis in Degenerative Aortic Stenosis

NCT046366841 location

Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure Changes in Organ-Specific Amyloid Load

NCT069748771 location